S

Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252

Watchlist Manager
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Watchlist
Price: 10.62 HKD 2.91% Market Closed
Market Cap: 10.3B HKD
Have any thoughts about
Shanghai MicroPort MedBot Group Co Ltd?
Write Note

Shanghai MicroPort MedBot Group Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicroPort MedBot Group Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Cash & Cash Equivalents
ÂĄ507.7m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Cash & Cash Equivalents
ÂĄ1.3B
CAGR 3-Years
120%
CAGR 5-Years
70%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cash & Cash Equivalents
ÂĄ6.5B
CAGR 3-Years
35%
CAGR 5-Years
57%
CAGR 10-Years
36%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cash & Cash Equivalents
ÂĄ20.5B
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Cash & Cash Equivalents
ÂĄ1.7B
CAGR 3-Years
11%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cash & Cash Equivalents
ÂĄ7.5B
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort MedBot Group Co Ltd
Glance View

Market Cap
10.2B HKD
Industry
Health Care

Shanghai MicroPort MedBot Group Co Ltd is a dynamic player in the medical innovation sector, strategically positioned at the crossroads of advanced technology and healthcare. Born out of a vision to revolutionize surgical practices, MedBot has dedicated itself to the development and commercialization of robotic-assisted systems. The company leverages cutting-edge research and development to create robotic platforms that aid surgeons in performing complex procedures with enhanced precision and control. Operating in a field where precision is paramount, MedBot's products are designed to minimize complications and reduce recovery times, catering to a global demand for improved surgical outcomes. MedBot generates its revenue by selling these sophisticated surgical robots to hospitals and healthcare institutions worldwide. Beyond the initial sale, the company benefits from offering ongoing service contracts, training, and support to ensure seamless integration and optimal performance of their products. Additionally, it capitalizes on the sale of consumables and replacement parts required for the long-term operation of their systems. Through its commitment to innovation and focus on addressing the complexities of surgical procedures, Shanghai MicroPort MedBot Group has carved out a distinctive niche, continually expanding its influence within the expanding scope of minimally invasive surgery.

Intrinsic Value
4.42 HKD
Overvaluation 58%
Intrinsic Value
Price
S

See Also

What is Shanghai MicroPort MedBot Group Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
507.7m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort MedBot Group Co Ltd's Cash & Cash Equivalents amounts to 507.7m CNY.

What is Shanghai MicroPort MedBot Group Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
-30%

Over the last year, the Cash & Cash Equivalents growth was -32%. The average annual Cash & Cash Equivalents growth rates for Shanghai MicroPort MedBot Group Co Ltd have been -30% over the past three years .

Back to Top